

**SMS PHARMACEUTICALS LIMITED**

**(CIN : L24239TG1987PLC008066)**


Regd. Office: Plot No.72, H.No.8-2-334/3&4, Road No.5, Opp.SBI Executive Enclave, Banjara Hills, Hyderabad-500 034, Telangana, India

Tel: +91-40-3535 9999, Fax :+91-40-2525 9889 ; Email : info@smspharma.com

Standalone Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2024

(Rs in Lakhs)

S.No	Particulars	Quarter Ended			Year Ended
		30-Jun-2024	31-Mar-2024	30-Jun-2023	31-Mar-2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income</b>				
	(a) Revenue from Operations	16,445.13	24,579.83	13,533.94	70,926.34
	(b) Other Income	136.76	164.57	51.29	445.97
	<b>Total Income</b>	<b>16,581.89</b>	<b>24,744.40</b>	<b>13,585.23</b>	<b>71,372.31</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of Materials Consumed	10,728.79	9,760.04	9,124.75	42,504.00
	(b) Changes in Inventories	(1,927.78)	6,322.49	(1,722.28)	(100.00)
	(c) Manufacturing Expenses	1,819.47	2,185.35	1,337.98	7,344.30
	(d) Employee Benefits Expense	1,688.38	2,012.21	1,448.28	6,414.97
	(e) Finance Cost	466.71	560.92	632.27	2,345.68
	(f) Depreciation and Amortization Expense	838.15	791.63	769.12	3,151.57
	(g) Other Expenses	789.78	951.05	679.44	3,078.62
	<b>Total Expenses - (a to g)</b>	<b>14,403.50</b>	<b>22,583.69</b>	<b>12,269.56</b>	<b>64,739.14</b>
<b>3</b>	<b>Profit/(loss) Before Exceptional and Extraordinary Items and Tax (1-2)</b>	<b>2,178.39</b>	<b>2,160.71</b>	<b>1,315.67</b>	<b>6,633.17</b>
<b>4</b>	Exceptional items	-	-	-	-
<b>5</b>	<b>Profit/(loss) Before Extraordinary Items and Tax (3-4)</b>	<b>2,178.39</b>	<b>2,160.71</b>	<b>1,315.67</b>	<b>6,633.17</b>
<b>6</b>	Extraordinary Items	-	-	-	-
<b>7</b>	<b>Profit/(loss) Before Tax (5-6)</b>	<b>2,178.39</b>	<b>2,160.71</b>	<b>1,315.67</b>	<b>6,633.17</b>
<b>8</b>	Tax Expenses				
	(a) Current Tax relating to Current Period	530.00	450.00	340.00	1,500.00
	(b) Current Tax relating to Earlier Period	-	13.02	-	12.79
	(c) Deferred Tax	15.56	105.51	47.39	177.89
	<b>Total Tax Expense</b>	<b>545.56</b>	<b>568.53</b>	<b>387.39</b>	<b>1,690.68</b>
<b>9</b>	<b>Net Profit / (Loss) after Tax (7-8)</b>	<b>1,632.83</b>	<b>1,592.18</b>	<b>928.28</b>	<b>4,942.49</b>
<b>10</b>	<b>Other Comprehensive Income (OCI):</b>				
	<b>Items that will not be reclassified to profit or Loss:</b>				
	(i) Remeasurement gains/(losses) on defined benefit plans	(1.94)	31.73	(7.54)	7.04
	(ii) Income Tax effect on the above	0.49	(7.98)	1.90	(1.77)
	<b>Total Other comprehensive Income/(loss), net of tax</b>	<b>(1.45)</b>	<b>23.75</b>	<b>(5.64)</b>	<b>5.27</b>
<b>11</b>	<b>Total Comprehensive Income (9+10)</b>	<b>1,631.38</b>	<b>1,615.93</b>	<b>922.64</b>	<b>4,947.76</b>
<b>12</b>	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52
<b>13</b>	<b>Other Equity excluding revaluation reserves</b>				56,202.26
<b>14</b>	Earnings Per Equity Share of Re.1/- each	1.93	1.88	1.10	5.84
	Basic / Diluted (not annualised)				



**Notes:**

- 1 The above unaudited standalone financial results of SMS Pharmaceuticals Ltd ("the Company) has been reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on August 05,2024. The statutory auditors of the Company have carried out a limited review on the standalone financial results and expressed an unmodified conclusion thereon.
- 2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act,2013 ("the Act") read with relevant rules issued thereunder("INDAS) and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 The Company is engaged in the manufacture and sales of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 4 The Figures for the quarter ended March 31,2024 are the balancing figures between the audited figures in respect of the full financial year ended March 31,2024 and the unaudited published year to date figures upto third quarter ended December 31,2023.The figures have been reclassified/ regrouped wherever necessary to confirm to current period's classification.

Place: Hyderabad

Date : August 05, 2024



**For SMS Pharmaceuticals Limited**

A handwritten signature in blue ink, appearing to read "Ramesh Babu Potluri".

**Ramesh Babu Potluri**

**Chairman and Managing Director**

**DIN No : 00166381**



**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To  
The Board of Directors  
SMS Pharmaceuticals Limited  
Hyderabad.

1. We have reviewed the accompanying statement of unaudited financial results of SMS Pharmaceuticals Limited ("the Company"), for the quarter ended 30<sup>th</sup> June 2024("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited, primarily to inquiries of company personnel responsible for financial and accounting matters, and applying analytical and other review procedures to financial data and thus provide less assurance than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results has not been prepared in all material aspects in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad

Date: 05.08.2024

For Suryanarayana & Suresh.,  
Chartered Accountants  
Reg. No.006631S

V Nagendra Rao  
Partner  
M.No. 227679



UDIN: 24227679BKDIME5520

**SMS PHARMACEUTICALS LIMITED**

**(CIN : L24239TG1987PLC008066)**

Regd. Office: Plot No.72, H.No.8-2-334/3&4, Road No.5, Opp.SBI Executive Enclave, Banjara Hills, Hyderabad-500 034, Telangana, India

Tel: +91-40-3535 9999, Fax :+91-40-2525 9889 ; Email : info@smspharma.com

Consolidated Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2024

(Rs in Lakhs)

S.No	Particulars	Quarter Ended			Year Ended
		30-Jun-2024	31-Mar-2024	30-Jun-2023	31-Mar-2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income</b>				
	(a) Revenue from Operations	16,445.13	24,579.83	13,533.94	70,926.34
	(b) Other Income	136.76	164.57	51.29	445.97
	<b>Total Income</b>	<b>16,581.89</b>	<b>24,744.40</b>	<b>13,585.23</b>	<b>71,372.31</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of Materials Consumed	10,724.16	9,746.97	9,172.15	42,526.49
	(b) Changes in Inventories	(1,927.78)	6,322.49	(1,722.28)	(100.00)
	(c) Manufacturing Expenses	1,819.47	2,185.35	1,337.98	7,344.30
	(d) Employee Benefits Expense	1,688.38	2,012.21	1,448.28	6,414.97
	(e) Finance Cost	466.71	560.92	632.27	2,345.68
	(f) Depreciation and Amortization Expense	838.15	791.63	769.12	3,151.57
	(g) Other Expenses	789.78	951.05	679.44	3,078.62
	<b>Total Expenses - (a to g)</b>	<b>14,398.87</b>	<b>22,570.62</b>	<b>12,316.96</b>	<b>64,761.63</b>
<b>3</b>	<b>Profit/(loss) Before Exceptional and Extraordinary Items and Tax (1-2)</b>	<b>2,183.02</b>	<b>2,173.78</b>	<b>1,268.27</b>	<b>6,610.68</b>
<b>4</b>	Exceptional items	-	-	-	-
<b>5</b>	<b>Profit/(loss) Before Extraordinary Items and Tax (3-4)</b>	<b>2,183.02</b>	<b>2,173.78</b>	<b>1,268.27</b>	<b>6,610.68</b>
<b>6</b>	Extraordinary Items	-	-	-	-
<b>7</b>	<b>Profit/(loss) Before Tax (5-6)</b>	<b>2,183.02</b>	<b>2,173.78</b>	<b>1,268.27</b>	<b>6,610.68</b>
<b>8</b>	<b>Tax Expenses</b>				
	(a) Current Tax relating to Current Period	530.00	450.00	340.00	1,500.00
	(b) Current Tax relating to Earlier Period	-	13.02	-	12.79
	(c) Deferred Tax	15.56	105.51	47.39	177.89
	<b>Total Tax Expense</b>	<b>545.56</b>	<b>568.53</b>	<b>387.39</b>	<b>1,690.68</b>
<b>9</b>	<b>Net Profit / (Loss) after Tax (7-8)</b>	<b>1,637.46</b>	<b>1,605.25</b>	<b>880.88</b>	<b>4,920.00</b>
<b>10</b>	<b>Share of Profit/(Loss) in Associate, net of tax</b>	<b>10.48</b>	<b>122.65</b>	<b>53.28</b>	<b>62.60</b>
<b>11</b>	<b>Net Profit / (loss) after taxes and share of profit/(loss) from associate (9+10)</b>	<b>1,647.94</b>	<b>1,727.90</b>	<b>934.16</b>	<b>4,982.60</b>
<b>12</b>	<b>Other Comprehensive Income (OCI):</b>				
	<b>Items that will not be reclassified to profit or Loss:</b>				
	(i) Remeasurement gains/(losses) on defined benefit plans	(1.94)	31.73	(7.54)	7.04
	(ii) Income Tax effect on the above	0.49	(7.98)	1.90	(1.77)
	(iii) Share of Other Comprehensive Income in Associates	0.52	(2.15)	1.37	1.99
	(iv) Share of Income Tax effect on the above in Associates	(0.14)	0.55	(0.36)	(0.52)
	<b>Total Other comprehensive Income/(loss), net of tax</b>	<b>(1.07)</b>	<b>22.15</b>	<b>(4.64)</b>	<b>6.74</b>
<b>13</b>	<b>Total comprehensive Income (11+12)</b>	<b>1,646.87</b>	<b>1,750.05</b>	<b>929.52</b>	<b>4,989.34</b>
<b>14</b>	<b>Paid-up equity share capital (Face Value of Re.1/- each)</b>	<b>846.52</b>	<b>846.52</b>	<b>846.52</b>	<b>846.52</b>
<b>15</b>	<b>Other Equity excluding revaluation reserves</b>				<b>52,786.37</b>
<b>16</b>	<b>Earnings Per Equity Share of Re.1/- each</b>	<b>1.95</b>	<b>2.04</b>	<b>1.10</b>	<b>5.89</b>
	Basic / Diluted (not annualised)				



**Notes:**

- 1 The above unaudited consolidated financial results of SMS Pharmaceuticals Ltd ("the Company") has been reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on August 05,2024. The statutory auditors of the Company have carried out a limited review on the standalone financial results and expressed an unmodified conclusion thereon.
- 2 These Consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act,2013 ("the Act") read with relevant rules issued thereunder("INDAS) and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 VKT Pharma Private Limited is considered as an Associate Company for the consolidation. During the reporting period the Associate Company has converted its Compulsory Convertible Preference Shares (CCPS) into equity shares and as a result the Company's holding in Associate Company is reduced to 34.83% as on June, 30 2024 from 36.55%. Accordingly the results include appropriate share of the results of the said Associate. The Company has another Joint Venture "chemo SMS Enterprises SL" in which there were no financial operations during the reporting period.
- 4 Consolidated Financial Statements have been prepared by applying Accounting Standard "Ind AS 28 "Investments in Associates and Joint Ventures" as applicable under the Companies Act,2013 and applicable rules there under.
- 5 The Group is engaged in the manufacture and sales of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 6 The Figures for the quarter ended March 31,2024 are the balancing figures between the audited figures in respect of the full financial year ended March 31,2024 and the unaudited published year to date figures upto third quarter ended December 31,2023.The figures have been reclassified/ regrouped wherever necessary to confirm to current period's classification.

Place: Hyderabad

Date : August 05, 2024

**For SMS Pharmaceuticals Limited**

**Ramesh Babu Potluri,**

**Chairman and Managing Director**

**DIN No : 00166381**





**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To  
The Board of Directors  
SMS Pharmaceuticals Limited  
Hyderabad.

1. We have reviewed the accompanying Statement of Consolidated Unaudited financial results of SMS Pharmaceuticals Limited("the holding Company") and its share of the net profit after tax and total comprehensive income of its associate (the holding company and its associate hereinafter referred to as "the Group"), for the quarter ended June 30, 2024 ("the Statement").The Statement is being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015").
2. This Statement, which is the responsibility of the holding company's management and has been approved by the holding company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review is limited, primarily to inquiries of company personnel responsible for financial and accounting matters, and applying analytical and other review procedures to financial data and thus provide less assurance than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

*Suryanarayana & Suresh*



4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. The Statement includes the results of the following associate entity/ joint venture:
  - a) VKT Pharma Private Limited
  - b) Chemo SMS Enterprises SL
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 7, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The consolidated unaudited financial results includes the holding company's share of profit after tax of Rs10.48Lakhs for the quarter ended June 30,2024 and total comprehensive income of Rs.0.39 Lakhs for the quarter ended June 30,2024, as considered in the statement, in respect of the associate namely VKT Pharma Private Limited which have been reviewed by their auditor.
8. The consolidated financial results also includes the unaudited financial results of joint venture namely Chemo SMS Enterprises SL in which there is no operations during the quarter ended June 30,2024. Hence, there is no significant effect on the financial statements and not material to the group.
9. Our conclusion on the Statement is not modified in respect of the above matters.

Place: Hyderabad  
Date: 05.08.2024

UDIN: 24227679BKDIMF7325

For Suryanarayana & Suresh.,  
Chartered Accountants  
Reg. No.006631S

V Nagendra Rao  
Partner  
M. No. 227679

